Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amgen’s KAI Deal Pays Off With Positive Phase III Trial Of Sensipar Successor

This article was originally published in The Pink Sheet Daily

Executive Summary

Drug acquired for $315 million in cash from KAI in 2012 – AMG 416 – hits all primary and secondary endpoints in first pivotal study of hyperparathyroidism in dialysis patients; two other trials have yet to report.

You may also be interested in...



Kidney Disease: A Price-Sensitive Market But A Bundle Of Opportunity

Medicare’s bundling policy for drugs and services in dialysis has turned on the pricing pressure in kidney disease. The cost containment policies have negatively impacted sales of some drugs and put a spotlight on growing costs in chronic kidney disease and end-stage renal disease. Nonetheless, there is plenty of opportunity for new drugs that can address the area’s unmet medical need, especially if they can help to reduce broader health care spending. That will require demonstrating value to payors and providers, however, particularly for drugs that treat secondary conditions associated with kidney disease.

Amgen Planned Acquisition Of KAI Would Bring In Replacement For Sensipar

Amgen will get KAI’s late-stage-ready asset for a small upfront price and gives itself a logical line extension to its chronic kidney disease drug Sensipar.

Rare Disease Roundtable: Dealing With Pricing Pressure

Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS077447

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel